Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22669877 | 0.96 | CA1 (0.55) | HIF1AMEN1KMT2ACYP17A1NAMPT | |
| SCHEMBL15996891 | 0.87 | SMN1; SMN2 (0.53) | HIF1AMEN1KMT2ACYP17A1NAMPT | |
| SCHEMBL1854209 | 0.87 | ATM (0.56) | CYP17A1NAMPTAURKARPS6KB1CA1 | |
| SCHEMBL13879810 | 0.87 | CYP17A1 (0.55) | HIF1AMEN1KMT2ACYP17A1NAMPT | |
| SCHEMBL1963813 | 0.86 | AURKA (0.52) | HIF1AAURKARPS6KB1CA1CA2 | |
| SCHEMBL30270551 | 0.86 | AURKA (0.57) | HIF1AAURKARPS6KB1CA1CA2 | |
| SCHEMBL25920561 | 0.86 | NAMPT (0.59) | HIF1AMEN1KMT2ANAMPTCA1 | |
| SCHEMBL775002 | 0.84 | NAMPT (0.56) | MEN1KMT2ACYP17A1NAMPTCA1 | |
| SCHEMBL10249437 | 0.84 | CYP17A1 (0.68) | CYP17A1NAMPTCA1CA2DRD2 | |
| SCHEMBL7042995 | 0.84 | DRD2 (0.59) | CYP17A1NAMPTCA1DRD2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4164622-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | Icahn School of Medicine at Mount Sinai (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2021257544-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | HIF1A 3198/4885MEN1 2558/4885KMT2A 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.